Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): A multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol
Trial design: We present a study protocol for a multi-centre, randomised, double-blind, parallel-group, placebo-controlled trial that seeks to test the feasibility, acceptability and effectiveness of a 52-week period of treatment with the first-in-class co-stimulatory blocker abatacept for preventing or delaying the onset of inflammatory arthritis. Methods: The study aimed to recruit 206 male or female subjects from the secondary care hospital setting across the UK and the Netherlands. Participants who were at least 18 years old, who reported inflammatory sounding joint pain (clinically suspic... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2019 |
Verlag/Hrsg.: |
BioMed Central Ltd.
|
Schlagwörter: | Abatacept / Antibodies to citrullinated protein antigens / At risk / Autoantibodies / Double-blind / Intervention / Placebo-controlled / Pre-clinical phase / Randomised / Rheumatoid arthritis / Antirheumatic Agents / Arthritis / Rheumatoid / Biomarkers / Double-Blind Method / Drug Administration Schedule / Feasibility Studies / Female / Humans / Male / Multicenter Studies as Topic / Netherlands / Pregnancy / Randomized Controlled Trials as Topic / Time Factors / Treatment Outcome / United Kingdom / Settore MED/16 - REUMATOLOGIA |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-28777596 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/10807/168298 |